Biotech · Private company
Croma-Pharma GmbH
Track this companyFree. Adds Croma-Pharma GmbH to your Dealase workspace and tells you when its record changes.
Clinical trials60 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- Botulinum Toxin APhase 3 · Glabellar Frown LinesClinicalTrials.gov · fetched Nov 12, 2026
- Botulinum Toxin A - Open LabelPhase 3 · Glabellar Frown LinesClinicalTrials.gov · fetched Nov 12, 2026
- Juvéderm® Voluma™ XCPhase 3 · Moderate to Severe Midface Volume DeficitClinicalTrials.gov · fetched Nov 12, 2026
- saypha® VOLUME LidocainePhase 3 · Moderate to Severe Midface Volume DeficitClinicalTrials.gov · fetched Nov 12, 2026
- Botulinum toxin A "BoNT/A-DP"Phase 2 · Frown LinesClinicalTrials.gov · fetched Nov 12, 2026
- Botulinum toxin A "Botox Cosmetics"Phase 2 · Frown LinesClinicalTrials.gov · fetched Nov 12, 2026
- Princess Filler LidocaineDermatological Non-DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Saypha® VOLUME Lidocaine for Midface AugmentationPHASE3 · COMPLETED · started Aug 16, 2022ClinicalTrials.gov NCT05386030 · fetched Nov 12, 2026
- Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown LinesPHASE2 · COMPLETED · started Jun 24, 2020ClinicalTrials.gov NCT04763265 · fetched Nov 12, 2026
- Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)NA · COMPLETED · started Jun 4, 2019ClinicalTrials.gov NCT03990883 · fetched Nov 12, 2026
- Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)PHASE3 · COMPLETED · started Apr 29, 2019ClinicalTrials.gov NCT03985982 · fetched Nov 12, 2026
- Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study IIPHASE3 · COMPLETED · started Mar 30, 2016ClinicalTrials.gov NCT02677805 · fetched Nov 12, 2026
- Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study IPHASE3 · COMPLETED · started Mar 2, 2016ClinicalTrials.gov NCT02677298 · fetched Nov 12, 2026